Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May 1;30(5):519-527.
doi: 10.1097/SPV.0000000000001461.

Regenerative Medicine in Urogynecology: Where We Are and Where We Want to Be

Affiliations
Review

Regenerative Medicine in Urogynecology: Where We Are and Where We Want to Be

Tatyanna Henderson et al. Urogynecology (Phila). .

Abstract

Pelvic floor disorders (PFDs) constitute a major public health issue given their negative effect on quality of life for millions of women worldwide and the associated economic burden. As the prevalence of PFDs continues to increase, novel therapeutic approaches for the effective treatment of these disorders are urgently needed. Regenerative medicine techniques, including cellular therapies, extracellular vesicles, secretomes, platelet-rich plasma, laser therapy, and bioinductive acellular biomaterial scaffolds, are emerging as viable clinical options to counteract urinary and fecal incontinence, as well as pelvic organ prolapse. This brief expert review explores the current state-of-science regarding application of these therapies for the treatment of PFDs. Although regenerative approaches have not been widely deployed in clinical care to date, these innovative techniques show a promising safety profile and potential to positively affect the quality of life of patients with PFDs. Furthermore, investigations focused on regeneration of the main constituents of the pelvic floor and lower urinary tract improve our understanding of the underlying pathophysiology of PFDs. Regenerative medicine techniques have a high potential not only to revolutionize treatment of PFDs but also to prevent these complex conditions.

PubMed Disclaimer

Conflict of interest statement

T.H. has declared that there are no conflicts of interest.

Figures

FIGURE 1.
FIGURE 1.
Schematic summarizing clinical and preclinical studies focused on the regenerative medicine in female pelvic medicine that are included in this narrative review. Created with BioRender.com.

Similar articles

Cited by

References

    1. Hallock JL, Handa VL. The epidemiology of pelvic floor disorders and childbirth: an update. Obstet Gynecol Clin North Am. 2016;43(1): 1–13. doi:10.1016/j.ogc.2015.10.008. - DOI - PMC - PubMed
    1. Gargett CE, Schwab KE, Zillwood RM, et al. Isolation and culture of epithelial progenitors and mesenchymal stem cells from human endometrium. Biol Reprod. 2009;80(6):1136–1145. doi:10.1095/biolreprod.108.075226. - DOI - PMC - PubMed
    1. Bozorgmehr M, Gurung S, Darzi S, et al. Endometrial and menstrual blood mesenchymal stem/stromal cells: biological properties and clinical application. Front Cell Dev Biol. 2020;8:497. doi:10.3389/fcell.2020.00497. - DOI - PMC - PubMed
    1. Kibschull M, Nguyen TTN, Chow T, et al. Differentiation of patient-specific void urine-derived human induced pluripotent stem cells to fibroblasts and skeletal muscle myocytes. Sci Rep. 2023;13(1): 4746. doi:10.1038/s41598-023-31780-9. - DOI - PMC - PubMed
    1. Sun DZ, Abelson B, Babbar P, et al. Harnessing the mesenchymal stem cell secretome for regenerative urology. Nat Rev Urol. 2019;16(6): 363–375. doi:10.1038/s41585-019-0169-3. - DOI - PMC - PubMed

Publication types